Neurocrine Biosciences (NBIX) : Asymmetry Capital Management scooped up 22,300 additional shares in Neurocrine Biosciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 63,188 shares of Neurocrine Biosciences which is valued at $3,074,728.Neurocrine Biosciences makes up approximately 7.27% of Asymmetry Capital Management’s portfolio.
Neurocrine Biosciences closed down -1.31 points or -2.75% at $46.24 with 7,25,091 shares getting traded on Wednesday. Post opening the session at $47.32, the shares hit an intraday low of $45.62 and an intraday high of $47.48 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Strs Ohio sold out all of its stake in NBIX during the most recent quarter. The investment firm sold 17,400 shares of NBIX which is valued $846,684. Rhenman Partners Asset Management Ab added NBIX to its portfolio by purchasing 60,000 company shares during the most recent quarter which is valued at $2,919,600. Neurocrine Biosciences makes up approx 0.53% of Rhenman Partners Asset Management Ab’s portfolio. Carl Domino Inc sold out all of its stake in NBIX during the most recent quarter. The investment firm sold 9,000 shares of NBIX which is valued $437,940.Traynor Capital Management reduced its stake in NBIX by selling 16,185 shares or 45.68% in the most recent quarter. The Hedge Fund company now holds 19,246 shares of NBIX which is valued at $936,510. Neurocrine Biosciences makes up approx 0.73% of Traynor Capital Management’s portfolio.Eagle Asset Management Inc reduced its stake in NBIX by selling 83,863 shares or 7.6% in the most recent quarter. The Hedge Fund company now holds 1,019,217 shares of NBIX which is valued at $44,621,320. Neurocrine Biosciences makes up approx 0.31% of Eagle Asset Management Inc’s portfolio.
On the company’s financial health, Neurocrine Biosciences reported $-0.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Feb 11, 2016. Analyst had a consensus of $-0.35.Analysts expectations of $ 2.86.During the same quarter in the previous year, the company posted $-0.26 EPS.
Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.